CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 22 enrolled
Drug / intervention
Fluticasone Propionate Nasal Spray +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01439815
NCT01439815Phase 4Completed

A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of Flonase (Fluticasone Propionate Nasal Spray) Compared to Placebo Nasal Spray in the Allergen BioCube (ABC) Model

ORA, Inc.·interventional·Posted Sep 23, 2011·Updated Apr 14, 2021

In Brief

A Phase 4 clinical trial evaluating Fluticasone Propionate Nasal Spray and Saline Nasal Spray for Allergic Rhinitis and Allergic Conjunctivitis. Completed, enrolled 22 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the onset of action of fluticasone propionate nasal spray compared to placebo nasal spray in reducing nasal allergic signs and symptoms following ragweed exposure in the Allergen BioCube (ABC) after up to 14 days of at home dosing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 23, 2011
Enrollment StartSep 1, 2011
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 14.8 years ago

Interventions

Fluticasone Propionate Nasal Spraydrug

two sprays in each nostril once daily

Saline Nasal Spraydrug

two sprays in each nostril once daily